“…In fact, of the small-molecule-based therapetics that were approved by the FDA in 2019, 8 of 32 (25%) contained a 2-aminopyridine (5 of 32) or 2-aminodiazine (3 of 32) motif (for examples, see Figure ). Thus, given the importance of 2-aminopyridines, the challenges associated with pyridine N -oxide and related chemistry, and the extreme conditions and narrow utility of the Chichibabin reaction, we aimed to develop conditions for the direct conversion of pyridines to 2-aminopyridines that would be applicable toward the functionalization of drug-like molecules. Specifically, the target reaction would need to occur with exquisite site selectivity, work directly on pyridines without preactivation, be tolerant of the protic and Lewis basic functionalities found in drug-like molecules, be able to be conducted on the benchtop without special precautions toward air or moisture, generate minimal waste, allow for simple purification, and employ only simple and readily available reagents …”